OAKLAND, Calif.--(BUSINESS WIRE)--Wites & Kapetan, P.A. is announcing their investigation of ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) and a possible class action lawsuit which may allege that the company and certain of its officers and directors committed violations of the Securities Exchange Act of 1934. Class action lawsuits already filed against ARIAD allege that on October 9, 2013, ARIAD reported that 11.8% of Iclusig-treated patients experienced serious arterial thrombosis. As a result, the Company said it was halting all enrollment in Iclusig clinical trials and that the Food and Drug Administration (FDA) had also placed a partial hold on the trials due to the serious arterial thrombosis occurring in Iclusig-treated patients. On October 9, 2013, ARIAD’s stock price declined by $11.31 per share, or 66%, to close at $5.83 per share.
If you are an investor who purchased ARIAD Common Stock between December 12, 2011 and October 8, 2013, you may have a legal claim against ARIAD and could serve as the lead plaintiff in the case. If you are interested in being the lead plaintiff, or would like to speak with an attorney about your legal rights, contact the attorneys at Wites & Kapetan, P.A. by email at email@example.com or toll-free at 1 (866) 277-8631.
Wites & Kapetan, P.A. is a law firm with offices in Oakland, California and Lighthouse Point, Florida, with expertise in the representation of investors in securities fraud and investor litigation claims. You may visit its website at www.wklawyers.com. Michele Desoer, an attorney at Wites & Kapetan, is a member of the State Bar of California and is responsible for the content of this advertisement.